Overview

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

Phase:

Phase 2

Details

Lead Sponsor:

Allergan

Treatments:

Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions